APA-话题@MedSci

#APA#

153篇内容 | 3643人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1338175, encodeId=782113381e582, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Alcami宣布与Solasia达成原料药darinaparsin生产协议, objectType=article, longId=120312, objectId=49a91203122c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49a91203122c, replyNumber=0, likeNumber=58, createdTime=2017-11-18, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49a91203122c, moduleTitle=Alcami宣布与Solasia达成原料药darinaparsin生产协议, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49a91203122c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338174, encodeId=fb4113381e4ea, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理, objectType=article, longId=117122, objectId=108811e122fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=108811e122fe, replyNumber=0, likeNumber=25, createdTime=2017-10-23, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=108811e122fe, moduleTitle=2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=108811e122fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338173, encodeId=3aff13381e311, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估, objectType=article, longId=117121, objectId=a79011e12171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a79011e12171, replyNumber=0, likeNumber=28, createdTime=2017-10-23, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a79011e12171, moduleTitle=2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a79011e12171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338172, encodeId=22b313381e2eb, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Lancet：Rucaparib可用于经铂类化疗后缓解的复发性卵巢癌患者的维持治疗。, objectType=article, longId=112754, objectId=8d18112e5477, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d18112e5477, replyNumber=0, likeNumber=57, createdTime=2017-09-15, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d18112e5477, moduleTitle=Lancet：Rucaparib可用于经铂类化疗后缓解的复发性卵巢癌患者的维持治疗。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d18112e5477)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338171, encodeId=33e813381e196, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Ann Oncol：apalutamide治疗去势耐受前列腺癌时，雄激素受体基因突变较少, objectType=article, longId=111171, objectId=0e551111e193, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e551111e193, replyNumber=0, likeNumber=74, createdTime=2017-08-30, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e551111e193, moduleTitle=Ann Oncol：apalutamide治疗去势耐受前列腺癌时，雄激素受体基因突变较少, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0e551111e193)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338170, encodeId=9b1d13381e0bc, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？, objectType=article, longId=108612, objectId=fcb31086129c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fcb31086129c, replyNumber=0, likeNumber=104, createdTime=2017-08-13, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fcb31086129c, moduleTitle=NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fcb31086129c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338169, encodeId=a60013381691e, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望, objectType=article, longId=108450, objectId=b39c1084500d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b39c1084500d, replyNumber=0, likeNumber=127, createdTime=2017-08-12, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b39c1084500d, moduleTitle=NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b39c1084500d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338168, encodeId=98c11338168d2, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=中国微循环学会亚太血管学术联盟(APA)大会, objectType=article, longId=99491, objectId=711e9949116, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e9949116, replyNumber=0, likeNumber=80, createdTime=2017-05-25, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e9949116, moduleTitle=中国微循环学会亚太血管学术联盟(APA)大会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e9949116)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338167, encodeId=f1af133816e18, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=FDA批准第三个PARPi卵巢癌新药niraparib, objectType=article, longId=93844, objectId=f2fd938442c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2fd938442c, replyNumber=0, likeNumber=76, createdTime=2017-03-30, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2fd938442c, moduleTitle=FDA批准第三个PARPi卵巢癌新药niraparib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2fd938442c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338166, encodeId=76a61338166ce, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=卵巢癌新药olaparib获3期临床突破, objectType=article, longId=92108, objectId=5ff2921087a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff2921087a, replyNumber=0, likeNumber=55, createdTime=2017-03-18, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff2921087a, moduleTitle=卵巢癌新药olaparib获3期临床突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ff2921087a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338165, encodeId=4822133816503, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL分享EFFORT研究结果：替比夫定优化治疗降低耐药率至3.3%, objectType=article, longId=90338, objectId=76a59033872, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76a59033872, replyNumber=0, likeNumber=0, createdTime=2017-03-03, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76a59033872, moduleTitle=APASL分享EFFORT研究结果：替比夫定优化治疗降低耐药率至3.3%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76a59033872)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338164, encodeId=7d18133816419, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=梅斯作为媒体参与亞太血管學術聯盟APA 澳門國際論壇暨2017澳門衛生局醫生協會國際學術年會, objectType=article, longId=90198, objectId=89f390198b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89f390198b2, replyNumber=0, likeNumber=88, createdTime=2017-03-02, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89f390198b2, moduleTitle=梅斯作为媒体参与亞太血管學術聯盟APA 澳門國際論壇暨2017澳門衛生局醫生協會國際學術年會, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89f390198b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338163, encodeId=c6841338163e0, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=热烈祝贺“2017第26届亚太肝脏研究学会年会APASL”圆满成功！, objectType=article, longId=89459, objectId=9ff489459e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9ff489459e7, replyNumber=0, likeNumber=55, createdTime=2017-02-22, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9ff489459e7, moduleTitle=热烈祝贺“2017第26届亚太肝脏研究学会年会APASL”圆满成功！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9ff489459e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338162, encodeId=f171133816211, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=[APASL访谈]杨希忠教授：为了没有肝炎的未来, objectType=article, longId=89411, objectId=f4588941131, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4588941131, replyNumber=0, likeNumber=72, createdTime=2017-02-22, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4588941131, moduleTitle=[APASL访谈]杨希忠教授：为了没有肝炎的未来, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4588941131)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338161, encodeId=8dbf1338161f8, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=FDA批准Clovis PARP抑制剂rucaparib, objectType=article, longId=84882, objectId=d7298488274, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7298488274, replyNumber=0, likeNumber=57, createdTime=2016-12-22, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7298488274, moduleTitle=FDA批准Clovis PARP抑制剂rucaparib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7298488274)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338160, encodeId=5a15133816080, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Napabucasin：胰腺癌克星？FDA授予孤儿药地位！, objectType=article, longId=82842, objectId=bb7f82842f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb7f82842f4, replyNumber=0, likeNumber=56, createdTime=2016-11-24, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb7f82842f4, moduleTitle=Napabucasin：胰腺癌克星？FDA授予孤儿药地位！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb7f82842f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338159, encodeId=4e3a13381590e, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=APASL 2017：第二十六届亚太肝病学会年会, objectType=article, longId=81770, objectId=305a81e70ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=305a81e70ba, replyNumber=0, likeNumber=57, createdTime=2016-11-05, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=305a81e70ba, moduleTitle=APASL 2017：第二十六届亚太肝病学会年会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=305a81e70ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338158, encodeId=d1b61338158f4, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=Circulation：稳定性缺血性心脏病应用vorapaxar治疗的有效性和安全性, objectType=article, longId=81402, objectId=2b6b814026b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b6b814026b, replyNumber=0, likeNumber=50, createdTime=2016-10-31, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b6b814026b, moduleTitle=Circulation：稳定性缺血性心脏病应用vorapaxar治疗的有效性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b6b814026b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338157, encodeId=a1af133815ef6, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=2016APASL共识指南——侵入性和非侵入性评估肝纤维化发布, objectType=article, longId=79687, objectId=71f1e9687dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71f1e9687dd, replyNumber=0, likeNumber=26, createdTime=2016-10-11, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71f1e9687dd, moduleTitle=2016APASL共识指南——侵入性和非侵入性评估肝纤维化发布, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=71f1e9687dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1338156, encodeId=bf051338156fe, content=<a href='/topic/show?id=cd2a262068' target=_blank style='color:#2F92EE;'>#APA#</a>, objectTitle=ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS, objectType=article, longId=79625, objectId=03fde96257d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03fde96257d, replyNumber=0, likeNumber=30, createdTime=2016-10-11, rootId=0, userName=12498b3em08(暂无昵称), userId=ce072500140, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03fde96257d, moduleTitle=ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03fde96257d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

APA

2020-05-29

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Alcami宣布与Solasia达成原料药darinaparsin生产协议

2017-11-18

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险管理

2017-10-23

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2017 AOCC/APAGE共识：接受抗肿瘤坏死因子治疗的炎症性肠病患者结核感染的风险评估

2017-10-23

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Lancet：Rucaparib可用于经铂类化疗后缓解的复发性卵巢癌患者的维持治疗。

2017-09-15

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Ann Oncol：apalutamide治疗去势耐受前列腺癌时，雄激素受体基因突变较少

2017-08-30

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

NEJM：BRCA生殖系突变阳性的晚期乳腺癌：奥拉帕尼（Olaparib）有力回天？

2017-08-13

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

NEJM：Olaparib为有BRCA突变的转移性乳腺癌患者带来希望

2017-08-12

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

中国微循环学会亚太血管学术联盟(APA)大会

2017-05-25

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

FDA批准第三个PARPi卵巢癌新药niraparib

2017-03-30

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

卵巢癌新药olaparib获3期临床突破

2017-03-18

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APASL分享EFFORT研究结果：替比夫定优化治疗降低耐药率至3.3%

2017-03-03

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

梅斯作为媒体参与亞太血管學術聯盟APA 澳門國際論壇暨2017澳門衛生局醫生協會國際學術年會

2017-03-02

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

热烈祝贺“2017第26届亚太肝脏研究学会年会APASL”圆满成功！

2017-02-22

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

[APASL访谈]杨希忠教授：为了没有肝炎的未来

2017-02-22

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

FDA批准Clovis PARP抑制剂rucaparib

2016-12-22

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Napabucasin：胰腺癌克星？FDA授予孤儿药地位！

2016-11-24

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

APASL 2017：第二十六届亚太肝病学会年会

2016-11-05

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

Circulation：稳定性缺血性心脏病应用vorapaxar治疗的有效性和安全性

2016-10-31

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

2016APASL共识指南——侵入性和非侵入性评估肝纤维化发布

2016-10-11

12498b3em08(暂无昵称) (审核中...)

前往app查看评论内容

#APA#

ESMO 2016：Niraparib可延长复发性卵巢癌患者的PFS

2016-10-11

科室
- - 订阅+
  - 更多科室
工具
服务